不同剂量洛伐他汀治疗78例冠心病合并高脂血症患者的临床疗效观察

目的 观察不同剂量洛伐他汀治疗冠心病合并高脂血症患者的临床疗效.方法 选择我院2011年3月-2012年3月78例冠心病合并高脂血症患者随机分为两组,A组39例患者给予常规剂量口服20mg/d洛伐他汀治疗,B组39例患者在A组常规剂量的基础上增加10mg/d洛伐他汀治疗,观察两组患者于治疗前后血脂指标变化情况及不良反应.结果 两组治疗后血脂各指标与治疗前比较差异具有显著性,B组治疗效果明显好于A组,两组比较差异具有显著性,有统计学意义（P 〈0.05）.B组治疗8周后TC达标28例,达标率为71.79%,LDL-C达标31例,达标率为79.49%,与A组比较差异具有显著性,有统计学意义（P 〈0.05）.A组出现不良反应3例,不良反应率7.69%,B组不良反应5例,不良反应率12.82%,均为轻度腹泻,两组不良反应比较差异无显著性,无统计学意义（P 〉0.05）.结论 不同剂量洛伐他汀治疗冠心病合并高脂血症的临床疗效有很大的差别,增大洛伐他汀剂量治疗后患者各方面指标均好于常规洛伐他汀剂量治疗,且增大剂量后无明显不良反应,建议临床治疗时可提高洛伐他汀剂量,以提高治疗效果.

The observation of the clinical efficacy for different doses of lovastatin in the treatment of 78 cases of patients with coronary heart disease and hyperlipidemia

Objective To observe the clinical efficacy for different doses of lovastatin in the treatment of 78 cases of patients with coronary heart disease and hyperlipidemia.Methods 78 cases of coronary heart disease in patients with hyperlipidemia in our hospital from March 2011 to March 2012 were randomly divided into two groups.A group of 39 patients were treated with conventional oral dose of 20mg/d lovastatin treatment,and group B of 39 patients increased 10mg/d lovastatin treatment on the basis of the regular dose of group A.The changes in lipid parameters before and after treatment and adverse reactions were observed.Results After treatment,the indicators of blood lipid had significant difference for the two groups tan before treatment.The treatment effect of group B was significantly better than group A,the difference was significant,there was statistically significant,P <0.05.TC standards was in 28 cases after treatment of 8 weeks in group B,the compliance rate was 71.79%,LDL-C standard was in 31 cases,the compliance rate was 79.49%.Compared with group A,the difference was significant,there was statistically significance,P <0.05.There were 3 cases of adverse reactions in group A,the adverse reaction rate was 7.69%,There were 5 cases of adverse reactions in group B,the rate of adverse events was 12.82%,they were all mild abdominal diarrhea,two sets of adverse reactions was with no significant difference,there was no statistically significance,P >0.05.Conclusion The clinical efficacy of different doses of lovastatin in the treatment of patients with coronary heart disease and hyperlipidemia is with significant difference.The various indicators of increasing the dose of lovastatin are better than conventional lovastatin dose treatment,and there was no significant adverse reaction after increasing doses.Therefore,it is recommended clinical treatment should improve the dose of lovastatin,in order to improve the therapeutic effect.